Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
Melanie A. Krook, Alexandria Lenyo, Max Wilberding, et al.
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 3, pp. 847-857
Open Access | Times Cited: 114

Showing 1-25 of 114 citing articles:

Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 3, pp. 228-239
Open Access | Times Cited: 318
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
Melanie A. Krook, Julie W. Reeser, Gabrielle Ernst, et al.
British Journal of Cancer (2020) Vol. 124, Iss. 5, pp. 880-892
Open Access | Times Cited: 256
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Ian M. Silverman, Antoine Hollebecque, Luc Friboulet, et al.
Cancer Discovery (2020) Vol. 11, Iss. 2, pp. 326-339
Open Access | Times Cited: 210
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors HarboringFGF/FGFRAberrations: A Phase I Dose-Expansion Study
Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro, et al.
Cancer Discovery (2021) Vol. 12, Iss. 2, pp. 402-415
Open Access | Times Cited: 200
Targeting FGFR inhibition in cholangiocarcinoma
Lipika Goyal, Sarinya Kongpetch, Valerie Crolley, et al.
Cancer Treatment Reviews (2021) Vol. 95, pp. 102170-102170
Open Access | Times Cited: 137
FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
Anuhya Kommalapati, Sri Harsha Tella, Mitesh J. Borad, et al.
Cancers (2021) Vol. 13, Iss. 12, pp. 2968-2968
Open Access | Times Cited: 118
FGFR-TKI resistance in cancer: current status and perspectives
Sitong Yue, Yukun Li, Xiaojuan Chen, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 115
Practical considerations in screening for genetic alterations in cholangiocarcinoma
Tanios Bekaii‐Saab, John Bridgewater, Nicola Normanno
Annals of Oncology (2021) Vol. 32, Iss. 9, pp. 1111-1126
Open Access | Times Cited: 108
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Sumera I. Ilyas, Silvia Affò, Lipika Goyal, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 7, pp. 470-486
Open Access | Times Cited: 92
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
J.E. Berchuck, Francesco Facchinetti, Daniel DiToro, et al.
Annals of Oncology (2022) Vol. 33, Iss. 12, pp. 1269-1283
Open Access | Times Cited: 86
Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
Jordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1645-1654
Open Access | Times Cited: 21
Targeting FGFR for cancer therapy
Pei Zhang, Lin Yue, Qingqing Leng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 16
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Recent advances of immunotherapy for biliary tract cancer
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Review of Gastroenterology & Hepatology (2020) Vol. 15, Iss. 5, pp. 527-536
Closed Access | Times Cited: 116
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Opinion on Investigational Drugs (2020) Vol. 30, Iss. 4, pp. 317-324
Open Access | Times Cited: 84
Therapy of Primary Liver Cancer
Mei Feng, Yisheng Pan, Ruirui Kong, et al.
The Innovation (2020) Vol. 1, Iss. 2, pp. 100032-100032
Open Access | Times Cited: 78
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100337-100337
Open Access | Times Cited: 77
FGFR2Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
James M. Cleary, Srivatsan Raghavan, Qibiao Wu, et al.
Cancer Discovery (2021) Vol. 11, Iss. 10, pp. 2488-2505
Open Access | Times Cited: 71
Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review
Jia Zheng, Wei Zhang, Linfeng Li, et al.
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 52
Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
Qibiao Wu, Haley Ellis, Giulia Siravegna, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 1, pp. 198-208
Open Access | Times Cited: 39
FGFR families: biological functions and therapeutic interventions in tumors
Qing Liu, Jiyu Huang, Weiwei Yan, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 36
Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
Marine Valéry, Damien Vasseur, Francesco Fachinetti, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4446-4446
Open Access | Times Cited: 27
Advances in targeted therapy of cholangiocarcinoma
Yuhang Li, Jianfeng Yu, Yujing Zhang, et al.
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 13
Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers
Khine Shan, Shivani Dalal, Nyein Nyein Thaw Dar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 849-849
Open Access | Times Cited: 11
The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma
Stephan Spahn, Fabian Kleinhenz, Ekaterina Shevchenko, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top